跳到正文
原文
Medical Xpress·· 2026-10-14精选AI 评分72

类风湿关节炎持续低疾病活动度患者阶梯减量b/tsDMARD,24周非劣于继续治疗

Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity

AI 导读

一项24周随机非劣效试验显示,对已持续低疾病活动度的类风湿关节炎患者阶梯减量生物制剂或靶向合成DMARD,在维持疾病控制上非劣于继续原剂量治疗。符合方案人群中,继续治疗组与减量组分别有89.6%和88.2%维持低疾病活动度,风险差-1.43个百分点(95% CI -8.9至5.23);多数病情加重者经方案指导重新加量后恢复低疾病活动度,两组不良事件均不常见。

推荐理由

24周随机非劣效试验显示,达标后阶梯减量在维持低疾病活动度上与继续用药相当,为减轻治疗负担提供参考。

正文
medicine
Credit: Unsplash/CC0 Public Domain

For patients with rheumatoid arthritis (RA) with sustained low disease activity (LDA), structured tapering of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) is noninferior to treatment continuation for maintaining disease control over 24 weeks, according to a study published online Oct. 6 in Arthritis & Rheumatology.

Dong-Jin Park, MD, Ph.D., from Chonnam National University Medical School and Hospital in Gwangju, South Korea, and colleagues examined the efficacy and safety of a structured b/tsDMARD tapering strategy in patients with RA who had achieved sustained LDA in a 24-week, randomized, noninferiority trial. Patients with RA receiving stable-dose b/tsDMARDs and maintaining Disease Activity Score-28 using erythrocyte sedimentation rate-defined LDA for at least six months were randomly assigned to stepwise dose tapering or dose continuation (171 and 177 patients, respectively).

The researchers found that LDA was maintained in 89.6% and 88.2% of patients in the continuation and tapering groups, respectively, in the per-protocol population, with a risk difference of −1.43 percentage points (95% confidence interval, −8.9 to 5.23), meeting the noninferiority criterion. In the full analysis set, findings were similar. For most patients experiencing disease worsening, LDA was regained after protocol-guided treatment re-escalation during follow-up. Comparable secondary outcomes were seen between the groups, although some disease activity measures favored continuation. Adverse events occurred infrequently in both groups.

"With careful patient selection, close monitoring and timely treatment re-escalation when needed, dose tapering may reduce treatment burden while maintaining disease control and health-related quality of life," the authors write.

More information

Dong‐Jin Park et al., Outcomes of Tapering Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs in Rheumatoid Arthritis: A Multicenter Randomized Noninferiority Trial, Arthritis & Rheumatology (2026). DOI: 10.1002/art.70363

Key medical concepts

Rheumatoid Arthritis

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Andrew Zinin

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

© 2026 HealthDay. All rights reserved.

Citation: Drug tapering noninferior to treatment continuation for rheumatoid arthritis with low disease activity (2026, October 13) retrieved 13 October 2026 from https://medicalxpress.com/news/2026-10-drug-tapering-noninferior-treatment-rheumatoid.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com